TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma
Anna D. Louie, Kelsey E. Huntington, Young Shin Lee, Jared Mompoint, Laura Jinxuan Wu, Seulki Lee, Thomas J. Miner, Wafik S. El‐Deiry
This study shows that combining TLY012 with PD-1 inhibition reduces PDAC tumor growth in mice by enhancing proinflammatory cytokines and immune cell infiltration.
American Journal of Cancer Research · Jan 1, 2025Peer-reviewedCancer Biology